Catalent Pharma Solutions Announces Agreement For One Of The First Regenerative Therapies To Employ iPS Cells In Humans WithCiRA, Kyoto University
Published: Mar 10, 2014
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent Pharma Solutions, the global leader in advanced delivery technologies and development solutions for drug, biologic and consumer health products, today announced an agreement with the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan to make a major advancement toward one of the first regenerative human therapies with induced pluripotent stem (iPS) cells applicable to humans. Under this agreement, Catalent manufactures an anti-CORIN monoclonal antibody using its proprietary GPEx® cell line expression technology for a planned clinical research project to develop an iPS cell-based transplant therapy for Parkinson’s disease at CiRA, which is directed by Professor Doctor Shinya Yamanaka, the joint winner of the Nobel Prize in Physiology or Medicine in 2012 for “the discovery that mature cells can be reprogrammed to become pluripotent.”
Help employers find you! Check out all the jobs and post your resume.